Stock News

Tourbillon Capital Partners LP Has Trimmed Sarepta Therapeutics (Call) (SRPT) Holding By $735,900; Senzar Asset Management Has Upped By $7.43 Million Its Express Scripts Hldg Co (ESRX) Stake

Tourbillon Capital Partners Lp decreased Sarepta Therapeutics Inc (Call) (SRPT) stake by 6.3% reported in 2017Q2 SEC filing. Tourbillon Capital Partners Lp sold 22,300 shares as Sarepta Therapeutics Inc (Call) (SRPT)’s stock rose 22.49%. The Tourbillon Capital Partners Lp holds 331,400 shares with $11.17M value, down from 353,700 last quarter. Sarepta Therapeutics Inc (Call) now has $3.51B valuation. The stock increased 1.01% or $0.54 during the last trading session, reaching $54.26. About 1.27 million shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since December 8, 2016 and is uptrending. It has outperformed by 80.12% the S&P500.

Senzar Asset Management Llc increased Express Scripts Hldg Co (ESRX) stake by 22.55% reported in 2017Q2 SEC filing. Senzar Asset Management Llc acquired 118,000 shares as Express Scripts Hldg Co (ESRX)’s stock declined 14.09%. The Senzar Asset Management Llc holds 641,301 shares with $40.94M value, up from 523,301 last quarter. Express Scripts Hldg Co now has $38.60B valuation. The stock increased 1.10% or $0.74 during the last trading session, reaching $68.15. About 2.81M shares traded. Express Scripts Holding Company (NASDAQ:ESRX) has declined 16.92% since December 8, 2016 and is downtrending. It has underperformed by 33.62% the S&P500.

Tourbillon Capital Partners Lp increased Macquarie Infrastructure Cor (NYSE:MIC) stake by 16,571 shares to 663,595 valued at $52.03M in 2017Q2. It also upped Cognizant Technology Solutio (NASDAQ:CTSH) stake by 1.49 million shares and now owns 1.99M shares. Portola Pharmaceuticals Inc (NASDAQ:PTLA) was raised too.

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on February, 27. They expect $-0.40 EPS, up 74.68% or $1.18 from last year’s $-1.58 per share. After $-0.78 actual EPS reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -48.72% EPS growth.

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 20 have Buy rating, 1 Sell and 6 Hold. Therefore 74% are positive. Sarepta Therapeutics had 93 analyst reports since August 5, 2015 according to SRatingsIntel. As per Friday, August 7, the company rating was downgraded by SunTrust. As per Friday, January 15, the company rating was downgraded by Piper Jaffray. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Wednesday, August 26 by TH Capital. On Friday, October 2 the stock rating was maintained by Needham with “Buy”. The rating was maintained by Needham with “Buy” on Thursday, October 26. Needham maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, February 22 with “Buy” rating. The rating was maintained by Jefferies on Tuesday, April 26 with “Hold”. Oppenheimer maintained the shares of SRPT in report on Wednesday, April 6 with “Outperform” rating. The rating was maintained by Credit Suisse with “Outperform” on Thursday, September 7. The rating was maintained by Piper Jaffray on Tuesday, July 25 with “Buy”.

Investors sentiment increased to 1.52 in Q2 2017. Its up 0.09, from 1.43 in 2017Q1. It is positive, as 19 investors sold SRPT shares while 41 reduced holdings. 30 funds opened positions while 61 raised stakes. 41.29 million shares or 4.20% more from 39.62 million shares in 2017Q1 were reported. Rock Springs Management Limited Partnership accumulated 0.35% or 205,000 shares. State Of Wisconsin Inv Board has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Tudor Et Al has 0.03% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Ameritas Prtnrs holds 0.01% or 4,561 shares in its portfolio. Nationwide Fund holds 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 29,466 shares. Architects holds 0% or 5 shares in its portfolio. Fmr Limited Com accumulated 0% or 1.09M shares. Blackrock Inc reported 5.22 million shares. Maryland-based Price T Rowe Assocs Inc Md has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Moreover, Qs Ltd Liability Corporation has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 2,600 shares. Goldman Sachs Grp Incorporated holds 813,968 shares. Vanguard Grp invested in 4.26 million shares. Nuveen Asset Lc owns 31,815 shares. Secor Capital Advisors Ltd Partnership reported 0.03% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Hightower Advsr Limited Liability Co reported 53,477 shares.

Investors sentiment decreased to 0.56 in 2017 Q2. Its down 0.07, from 0.63 in 2017Q1. It fall, as 113 investors sold ESRX shares while 436 reduced holdings. 75 funds opened positions while 234 raised stakes. 499.72 million shares or 1.80% less from 508.89 million shares in 2017Q1 were reported. Barrow Hanley Mewhinney And Strauss Lc, a Texas-based fund reported 20.31 million shares. Rhumbline Advisers holds 0.16% or 1.10M shares in its portfolio. Lombard Odier Asset Management (Europe) invested 0.03% of its portfolio in Express Scripts Holding Company (NASDAQ:ESRX). Andra Ap holds 0.14% in Express Scripts Holding Company (NASDAQ:ESRX) or 88,900 shares. Capstone Asset Mgmt accumulated 58,192 shares or 0.1% of the stock. Capital Fincl Advisers Ltd Liability has 69,085 shares. Raymond James Finance Inc holds 218,994 shares. C Gru Holdg A S holds 62,863 shares. 57,360 were reported by Glob Endowment Mngmt Limited Partnership. Monetary Mgmt Gp reported 5,310 shares. New Mexico Educational Retirement Board holds 0.17% of its portfolio in Express Scripts Holding Company (NASDAQ:ESRX) for 55,140 shares. Us State Bank De owns 534,338 shares or 0.11% of their US portfolio. Orca Invest Mngmt Limited Liability Co accumulated 7,056 shares. Loomis Sayles LP reported 346 shares. 4,632 were accumulated by Fernwood Management Ltd Co.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *